Pulmonx
Pulmonx Corporation is a medical technology company that specializes in developing minimally invasive devices for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company's primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation associated with emphysema; the Chartis Pulmonary Assessment System, which assesses collateral ventilation; and the StratX Lung Analysis Platform, a cloud-based service that analyzes lung imaging to optimize treatment strategies. Pulmonx aims to provide effective alternatives for patients who are symptomatic despite medical management and are ineligible for surgical interventions. The Zephyr Valve has received FDA pre-market approval and is in use in over 25 countries, with more than 76,000 valves employed to date in treating over 19,000 patients. Headquartered in Redwood City, California, Pulmonx serves a global market, including regions such as Europe, the Middle East, Africa, and Asia-Pacific.
Aeris Therapeutics, Inc. is a medical therapeutics company focused on developing and commercializing therapies for patients suffering from emphysema and other advanced lung diseases. The company provides the AeriSeal System, designed to reduce lung volume and enhance lung function in individuals with severe emphysema. This system enables physicians to utilize a bronchoscope to directly target and treat damaged areas within the lungs. Aeris Therapeutics serves both patients and healthcare professionals primarily in the United States and Europe. Founded in 2000 and based in Woburn, Massachusetts, the company underwent a name change from Bistech, Inc. to Aeris Therapeutics in 2004. It has a strong foundation in pulmonary medicine, complemented by significant expertise in preclinical and clinical research as well as product development.
Emphasys Medical is a company that develops therapeutic devices aimed at treating patients with emphysema and other chronic obstructive pulmonary diseases (COPD). Founded in 2000 and based in Redwood City, California, the company specializes in minimally invasive therapies. Its primary product, the Zephyr Endobronchial Valve system, is designed to block airflow through openings in the lung, facilitating the healing of damaged tissue. By addressing the gradual breakdown of lung tissue and loss of elasticity associated with emphysema, Emphasys Medical's solutions enable healthcare providers to manage COPD more effectively.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.